Chronic kidney disease studies can be particularly difficult to enroll. This devastating disease requires experience and long-term dedication from doctors, researchers, and patients. This Phase III study hinged on finding the best sites for the job.
We knew going in that the research sponsor, an international pharmaceutical company headquartered in Japan, and their CRO had a very strict criteria for feasibility and site selection.
That’s what we’re here for.
Finding success through physician referrals and chart reviews, the study’s enrollment criteria was met 100%, with overall retention remaining at 93% after one year.